BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 28384752)

  • 21. Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis.
    Sutedja NA; van der Schouw YT; Fischer K; Sizoo EM; Huisman MH; Veldink JH; Van den Berg LH
    J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):638-42. PubMed ID: 21471184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated levels of ferritin in the cerebrospinal fluid of amyotrophic lateral sclerosis patients.
    Zheng Y; Gao L; Wang D; Zang D
    Acta Neurol Scand; 2017 Aug; 136(2):145-150. PubMed ID: 27804118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elevated Levels of IFN-γ in CSF and Serum of Patients with Amyotrophic Lateral Sclerosis.
    Liu J; Gao L; Zang D
    PLoS One; 2015; 10(9):e0136937. PubMed ID: 26332465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Creatine kinase enzyme level correlates positively with serum creatinine and lean body mass, and is a prognostic factor for survival in amyotrophic lateral sclerosis.
    Rafiq MK; Lee E; Bradburn M; McDermott CJ; Shaw PJ
    Eur J Neurol; 2016 Jun; 23(6):1071-8. PubMed ID: 27029589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis.
    Thouvenot E; Demattei C; Lehmann S; Maceski-Maleska A; Hirtz C; Juntas-Morales R; Pageot N; Esselin F; Alphandéry S; Vincent T; Camu W
    Eur J Neurol; 2020 Feb; 27(2):251-257. PubMed ID: 31437330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blood Lead, Bone Turnover, and Survival in Amyotrophic Lateral Sclerosis.
    Fang F; Peters TL; Beard JD; Umbach DM; Keller J; Mariosa D; Allen KD; Ye W; Sandler DP; Schmidt S; Kamel F
    Am J Epidemiol; 2017 Nov; 186(9):1057-1064. PubMed ID: 29020133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
    Cudkowicz ME; van den Berg LH; Shefner JM; Mitsumoto H; Mora JS; Ludolph A; Hardiman O; Bozik ME; Ingersoll EW; Archibald D; Meyers AL; Dong Y; Farwell WR; Kerr DA;
    Lancet Neurol; 2013 Nov; 12(11):1059-67. PubMed ID: 24067398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secular Trends of Amyotrophic Lateral Sclerosis: The Piemonte and Valle d'Aosta Register.
    Chiò A; Mora G; Moglia C; Manera U; Canosa A; Cammarosano S; Ilardi A; Bertuzzo D; Bersano E; Cugnasco P; Grassano M; Pisano F; Mazzini L; Calvo A;
    JAMA Neurol; 2017 Sep; 74(9):1097-1104. PubMed ID: 28692730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic inflammation and subsequent risk of amyotrophic lateral sclerosis: Prospective cohort study.
    Batty GD; Kivimäki M; Frank P; Gale CR; Wright L
    Brain Behav Immun; 2023 Nov; 114():46-51. PubMed ID: 37543248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CSF glial markers correlate with survival in amyotrophic lateral sclerosis.
    Süssmuth SD; Sperfeld AD; Hinz A; Brettschneider J; Endruhn S; Ludolph AC; Tumani H
    Neurology; 2010 Mar; 74(12):982-7. PubMed ID: 20308682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Slower disease progression and prolonged survival in contemporary patients with amyotrophic lateral sclerosis: is the natural history of amyotrophic lateral sclerosis changing?
    Czaplinski A; Yen AA; Simpson EP; Appel SH
    Arch Neurol; 2006 Aug; 63(8):1139-43. PubMed ID: 16908741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival of patients with amyotrophic lateral sclerosis in a population-based registry.
    Millul A; Beghi E; Logroscino G; Micheli A; Vitelli E; Zardi A
    Neuroepidemiology; 2005; 25(3):114-9. PubMed ID: 15956808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis?
    Gille B; De Schaepdryver M; Dedeene L; Goossens J; Claeys KG; Van Den Bosch L; Tournoy J; Van Damme P; Poesen K
    J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1338-1346. PubMed ID: 31175169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy.
    Zoccolella S; Beghi E; Palagano G; Fraddosio A; Guerra V; Samarelli V; Lepore V; Simone IL; Lamberti P; Serlenga L; Logroscino G;
    Eur J Neurol; 2007 Mar; 14(3):262-8. PubMed ID: 17355545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-net.
    Steinacker P; Huss A; Mayer B; Grehl T; Grosskreutz J; Borck G; Kuhle J; Lulé D; Meyer T; Oeckl P; Petri S; Weishaupt J; Ludolph AC; Otto M
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Feb; 18(1-2):112-119. PubMed ID: 27819158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The serum lipid profiles of amyotrophic lateral sclerosis patients: A study from south-west China and a meta-analysis.
    Huang R; Guo X; Chen X; Zheng Z; Wei Q; Cao B; Zeng Y; Shang H
    Amyotroph Lateral Scler Frontotemporal Degener; 2015; 16(5-6):359-65. PubMed ID: 26121273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Insulin-like Growth Factor 1 Concentrations with Risk for and Prognosis of Amyotrophic Lateral Sclerosis - Results from the ALS Registry Swabia.
    Nagel G; Peter RS; Rosenbohm A; Koenig W; Dupuis L; Rothenbacher D; Ludolph AC
    Sci Rep; 2020 Jan; 10(1):736. PubMed ID: 31959864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measurement of cystatin C levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Ren Y; Zhu W; Cui F; Yang F; Chen Z; Ling L; Huang X
    Int J Clin Exp Pathol; 2015; 8(5):5419-26. PubMed ID: 26191245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic inflammation and subsequent risk of amyotrophic lateral sclerosis: prospective cohort study.
    Batty GD; Kivimäki M; Frank P; Gale CR; Wright L
    medRxiv; 2023 Mar; ():. PubMed ID: 36945398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum urate at trial entry and ALS progression in EMPOWER.
    O'Reilly ÉJ; Liu D; Johns DR; Cudkowicz ME; Paganoni S; Schwarzschild MA; Leitner M; Ascherio A
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Feb; 18(1-2):120-125. PubMed ID: 27677562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.